{"id":25432,"date":"2025-11-10T10:04:56","date_gmt":"2025-11-10T08:04:56","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/intelligenza-artificiale-generativa-nel-pharma\/"},"modified":"2025-11-18T18:06:20","modified_gmt":"2025-11-18T16:06:20","slug":"intelligenza-artificiale-generativa-nel-pharma","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/","title":{"rendered":"Generative AI in the Pharmaceutical Sector"},"content":{"rendered":"

Artificial intelligence has stopped being a laboratory experiment and has become an enabling technology for the pharmaceutical industry.
While early applications focused on drug discovery and predictive analysis of clinical data, today generative AI and large language models (LLMs)<\/strong> are redefining the entire value chain: from the search for new molecules to regulatory documentation, from pharmacovigilance to scientific communication.
Adoption is growing rapidly, but not without resistance. For many companies, the real barrier is no longer the technology itself, but the ability to integrate it in a compliant and sustainable way.<\/p>\n

AI as an accelerator for R&D<\/h2>\n

In research and development, generative AI makes it possible to simulate thousands of molecular combinations in silico, drastically reducing screening time and cost. LLMs can read and connect millions of scientific papers, extracting patterns not immediately visible to the human eye.
Early evidence shows that this synergy allows companies to anticipate preclinical validation phases by months, improving overall success rates. But the impact goes beyond discovery: generative models are already being used to draft study protocols, safety reports and regulatory summaries in language aligned with authorities\u2019 expectations.
The competitive advantage lies in the ability to turn knowledge into faster, better decision-making<\/strong>.<\/p>\n

Manufacturing and quality: next-generation AI on the shop floor<\/h2>\n

Pharmaceutical manufacturing is also benefiting from the generative revolution. AI systems are used to analyze process data in real time, predict deviations and optimize the quality of the final product.
With LLMs, companies can correlate technical and regulatory information, automatically suggesting corrective and improvement actions based on production history.
The result is a new paradigm of intelligence-driven smart manufacturing<\/strong>, where documentation becomes dynamic and self-updating, and quality departments evolve into predictive analytics hubs.<\/p>\n

The regulatory frontier<\/h2>\n

The most sensitive point remains alignment with regulators<\/strong>. The European Medicines Agency and the European Commission are defining guidelines on the use of artificial intelligence across the medicinal product lifecycle, especially in regulatory processes and pharmacovigilance.
Transparency, traceability and human oversight are the three guiding principles.
The risk of \u201cAI black boxes<\/strong>\u201d \u2014 algorithms that generate non-explainable results \u2014 is currently the main barrier to large-scale adoption. Authorities are requiring auditable systems, validated datasets and structured governance frameworks able to guarantee data quality and the integrity of outputs<\/p>\n

Governance e responsabilit\u00e0 dei dati<\/h2>\n

L\u2019AI generativa amplifica il valore ma anche la vulnerabilit\u00e0 dei dati. Ogni fase, dalla ricerca al post-marketing, produce enormi quantit\u00e0 di informazioni cliniche, genetiche e produttive che devono essere gestite in conformit\u00e0 con GDPR, GxP e normative etiche.
Le aziende stanno quindi sviluppando framework di governance integrata<\/strong> che bilanciano innovazione e compliance.
Le funzioni IT e qualit\u00e0 devono dialogare costantemente, costruendo infrastrutture che consentano di tracciare ogni decisione presa da un algoritmo e di verificarne l\u2019impatto. In assenza di una cultura del dato, l\u2019intelligenza artificiale rischia di trasformarsi da leva strategica a fattore di rischio reputazionale.<\/p>\n

Data governance and accountability<\/h2>\n

Generative AI amplifies both the value and the vulnerability of data. Every phase, from research to post-marketing, produces vast amounts of clinical, genetic and manufacturing information that must be managed in accordance with GDPR, GxP and ethical standards.
Companies are therefore developing integrated data-governance frameworks that balance innovation with compliance.
IT and quality functions must work together, building infrastructures that allow every AI-enabled decision to be traced and its impact verified. Without a strong data culture, artificial intelligence risks shifting from a strategic lever to a reputational liability.<\/p>\n

Impact on capabilities and leadership<\/h2>\n

The introduction of generative AI is reshaping required professional profiles. New hybrid roles are emerging \u2014 regulatory data scientists, AI compliance managers, prompt engineers for technical documentation \u2014 working at the intersection of technology and pharmaceutical science.
For executives, the challenge is twofold: understanding AI well enough to guide its integration, and creating trusted ecosystems<\/strong> where technology does not replace experts but amplifies their judgment.
Future competitive advantage will depend less on the algorithm itself and more on the quality of the decisions the algorithm helps enable.<\/p>\n

From the lab to the boardroom<\/h2>\n

Generative AI is no longer an IT project but a strategic business decision<\/strong>. Companies adopting it are revising governance models, risk management practices and relationships with technology partners.
Early experiences show that the most significant benefits arise when AI is integrated from the start into the innovation cycle: research, manufacturing, compliance and communication.
This requires long-term vision and sustained investment, but allows organizations to turn accumulated knowledge into scalable competitive value.<\/p>\n

Beyond technology: trust as the real enabler<\/h2>\n

At the heart of every successful digital transformation in pharma lies trust \u2014 trust in data, in algorithms and in the people who govern them.
Generative AI can accelerate the discovery of new treatments and improve the efficiency of the value chain, but only if embedded within a framework of ethics, transparency and shared responsibility.
The future of the sector will not depend on how sophisticated machines become, but on how intelligently we choose to use them<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Generative artificial intelligence is reshaping the pharmaceutical industry: it accelerates R&D, manufacturing and regulatory processes, yet it also demands new standards of governance, security and transparency. The challenge is to balance innovation with trust, turning technology into a strategic business driver.<\/p>\n","protected":false},"author":32,"featured_media":25361,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[837],"tags":[],"class_list":{"0":"post-25432","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-artificial-intelligence"},"yoast_head":"\nGenerative AI in the Pharmaceutical Sector - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"L\u2019AI generativa ridefinisce il pharma: accelera R&D, produzione e processi regolatori, ma impone nuove regole di governance, sicurezza e trasparenza.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Generative AI in the Pharmaceutical Sector - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"L\u2019AI generativa ridefinisce il pharma: accelera R&D, produzione e processi regolatori, ma impone nuove regole di governance, sicurezza e trasparenza.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-10T08:04:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-18T16:06:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-6-nov-2025-15_15_27-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\"},\"headline\":\"Generative AI in the Pharmaceutical Sector\",\"datePublished\":\"2025-11-10T08:04:56+00:00\",\"dateModified\":\"2025-11-18T16:06:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/\"},\"wordCount\":823,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-6-nov-2025-15_15_27.png\",\"articleSection\":[\"Artificial intelligence\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/\",\"name\":\"Generative AI in the Pharmaceutical Sector - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-6-nov-2025-15_15_27.png\",\"datePublished\":\"2025-11-10T08:04:56+00:00\",\"dateModified\":\"2025-11-18T16:06:20+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\"},\"description\":\"L\u2019AI generativa ridefinisce il pharma: accelera R&D, produzione e processi regolatori, ma impone nuove regole di governance, sicurezza e trasparenza.\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-6-nov-2025-15_15_27.png\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-6-nov-2025-15_15_27.png\",\"width\":1536,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Generative AI in the Pharmaceutical Sector\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Generative AI in the Pharmaceutical Sector - MakingPharmaIndustry","description":"L\u2019AI generativa ridefinisce il pharma: accelera R&D, produzione e processi regolatori, ma impone nuove regole di governance, sicurezza e trasparenza.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/","og_locale":"en_US","og_type":"article","og_title":"Generative AI in the Pharmaceutical Sector - MakingPharmaIndustry","og_description":"L\u2019AI generativa ridefinisce il pharma: accelera R&D, produzione e processi regolatori, ma impone nuove regole di governance, sicurezza e trasparenza.","og_url":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2025-11-10T08:04:56+00:00","article_modified_time":"2025-11-18T16:06:20+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-6-nov-2025-15_15_27-1024x683.png","type":"image\/png"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f"},"headline":"Generative AI in the Pharmaceutical Sector","datePublished":"2025-11-10T08:04:56+00:00","dateModified":"2025-11-18T16:06:20+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/"},"wordCount":823,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-6-nov-2025-15_15_27.png","articleSection":["Artificial intelligence"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/","url":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/","name":"Generative AI in the Pharmaceutical Sector - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-6-nov-2025-15_15_27.png","datePublished":"2025-11-10T08:04:56+00:00","dateModified":"2025-11-18T16:06:20+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f"},"description":"L\u2019AI generativa ridefinisce il pharma: accelera R&D, produzione e processi regolatori, ma impone nuove regole di governance, sicurezza e trasparenza.","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-6-nov-2025-15_15_27.png","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-6-nov-2025-15_15_27.png","width":1536,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/artificial-intelligence\/intelligenza-artificiale-generativa-nel-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Generative AI in the Pharmaceutical Sector"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/25432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=25432"}],"version-history":[{"count":3,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/25432\/revisions"}],"predecessor-version":[{"id":25435,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/25432\/revisions\/25435"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/25361"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=25432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=25432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=25432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}